In spite of advances in the molecular diagnosis of recessive dystrophic epidermolysis bullosa (RDEB), an inherited blistering disease due to a deficiency of type VII collagen at the basement membrane zone (BMZ) of stratified epithelium, current therapy is limited to supportive palliation. Gene delivery has shown promise in short-term experiments; however, its long-term sustainability through multiple turnover cycles in human tissue has awaited confirmation. To characterize approaches for long-term genetic correction, retroviral vectors were constructed containing long terminal repeat-driven full-length and epitope-tagged COL7A1 cDNA and evaluated for durability of type VII collagen expression and function in RDEB skin tissue regenerated on immune-deficient mice. Type VII collagen expression was maintained for 1 year in vivo, or over 12 epidermal turnover cycles, with no abnormalities in skin morphology or self-renewal. Type VII collagen restoration led to correction of RDEB disease features, including reestablishment of anchoring fibrils at the BMZ. This approach confirms durably corrective and noninjurious gene delivery to long-lived epidermal progenitors and provides the foundation for a human clinical trial of ex vivo gene delivery in RDEB.
Get full access to this article
View all access options for this article.
References
1.
BurgesonR.E.1993. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J. Invest. Dermatol., 101:252–255.
2.
ChenM., KasaharaN., KeeneD.R., ChanL., HoefflerW.K., FinlayD., BarcovaM., CannonP.M., MazurekC., WoodleyD.T.2002. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat. Genet., 32:670–675.
ChoateK.A., MedalieD.A., MorganJ.R., KhavariP.A.1996b. Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat. Med., 2:1263–1267.
5.
ChristianoA.M., GreenspanD.S., Lees, UittoJ.1994a. Cloning of human type VII collagen. Complete primary sequence of the α1(VII) chain and identification of intragenic polymorphisms. J. Biol. Chem., 269:20256–20262.
6.
ChristianoA.M., HoffmanG.G., Chung-HonetL.C., LeeS., ChengW., UittoJ., GreenspanD.S.1994bStructural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. Genomics, 21:169–179.
7.
De LucaM., AlbaneseE., BondanzaS., MegnaM., UgozzoliL., MolinaF., CanceddaR., SantiP.L., BormioliM., StellaM., MagliacaniG.1989. Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state. Burns, 15:303–309.
DengH., ChoateK.A., UnQ., KhavariP.A.1998. High-efficiency gene transfer and pharmacologic selection of genetically engineered human keratinocytes. Biotechniques, 25:274–280.
10.
Di NunzioF., MaruggiG., FerrariS., Di IorioE., PolettiV., GarciaM., Del RioM., De LucaM., LarcherF., PellegriniG., MavilioF.2008. Correction of laminin-5 deficiency in human epidermal stern cells by transcriptionally targeted lentiviral vectors. Mol. Ther., 16:1977–1985.
11.
EadyR.A., DunnillM.G.1994. Epidermolysis bullosa: Hereditary skin fragility diseases as paradigms in cell biology. Arch. Dermatol. Res., 287:2–9.
12.
EdingerM., SvveeneyT.J., TuckerA.A., OlomuA.B., NegrinR.S., ContagC.H.1999. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia, 1:303–310.
13.
GacheY., BaldeschiC., Del RioM., Gagnoux-PalaciosL., LarcherF., LacourJ.P., MeneguzziG.2004. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum. Gene Ther., 15:921–933.
14.
GreenH.1980. The keratinocyte as differentiated cell type. Harvey Lect., 74:101–139.
15.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., Le DeistF., WulffraatN., McintyreE., RadfordI., VillevalJ.L., FraserC.C., Cavazzana-CalvoM., FischerA.2003a. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348:255–256.
16.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., McCormackM.P., WulffraatN., LeboulchP., LimA., OsborneC.S., PawliukR., MorillonE., SorensenR., ForsterA., FraserP., CohenJ.I., de Saint BasileG., AlexanderI., WintergerstU., FrebourgT., AuriasA., Stoppa-LyonnetD., RomanaS., Radford-WeissI., GrossF., ValensiF., DelabesseE., MacintyreE., SigauxF., SoulierJ., LeivaL.E., WisslerM., PrinzC., RabbittsT.H., Le DeistF., FischerA., Cavazzana-CalvoM.2003b. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302:415–419.
17.
HeagertyA.H., KennedyA.R., LeighI.M., PurkisP., EadyR.A.1986. Identification of an epidermal basement membrane defect in recessive forms of dystrophic epidermolysis bullosa by LH 7:2 monoclonal antibody: Use in diagnosis. Br. J. Dermatol., 115:125–131.
18.
KernJ.S., LoeckermannS., FritschA., HausserL., RothW., MaginT.M., MackC., MullerM.L., PaulO., RutherP., Bruckner-TudermanL.2009. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: High stability of collagen VII favors long-term skin integrity. Mol. Ther., 17:1605–1615.
19.
KinsellaT.M., NolanG.P.1996. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther., 7:1405–1413.
20.
KohnD.B., SadelainM., DunbarC., BodineD., KiemH.P., CandottiF., TisdaleJ., RiviereI., BlauC.A., RichardR.E., SorrentinoB., NoltaJ., MalechH., BrennerM., CornettaK., CavagnaroJ., HighK., GloriosoJ.American Society of Gene Therapy (ASGT). 2003. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther., 8:180–187.
21.
KorgeB.P., KriegT.1996. The molecular basis for inherited bullous diseases. J. Mol. Med., 74:59–70.
22.
LapiereJ.C., WoodleyD.T., ParenteM.G., IwasakiT., WynnK.C., ChristianoA.M., UittoJ.1993. Epitope mapping of type VII collagen: Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J. Clin. Invest., 92:1831–1839.
23.
LeighI.M., EadyR.A., HeagertyA.H., PurkisP.E., WhiteheadP.A., BurgesonR.E.1988. Type VII collagen is a normal component of epidermal basement membrane, which shows altered expression in recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol., 90:639–642.
24.
MarinkovichM.P.1993. The molecular genetics of basement membrane diseases. Arch. Dermatol., 129:1557–1565.
25.
MavilioF., PellegriniG., FerrariS., Di NunzioF., Di IorioE., RecchiaA., MaruggiG., FerrariG., ProvasiE., BoniniC., CapurroS., ContiA., MagnoniC., GiannettiA., De LucaM.2006. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med., 12:1397–1402.
26.
MillerA.D., GarciaJ.V., Von SuhrN., LynchC.M., WilsonC., EidenM.V.1991. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol., 65:2220–2224.
27.
Ortiz-UrdaS., ThyagarajanB., KeeneD.R., UnQ., FangM., CalosM.P., KhavariP.A.2002. Stable nonviral genetic correction of inherited human skin disease. Nat. Med., 8:1166–1170.
28.
Ortiz-UrdaS., LinQ., GreenC.L., KeeneD.R., MarinkovichM.P., KhavariP.A.2003. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest., 111:251–255.
29.
Ortiz-UrdaS., GarciaJ., GreenC.L., ChenL., UnQ., VeitchD.P., SakaiL.Y., LeeH., MariniovichM.P., KhavariP.A.2005. Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science, 307:1773–1776.
30.
PallerA.S.1996. The genetic basis of hereditary blistering disorders. Curr. Opin. Pediatr., 8:367–371.
31.
PellegriniG., BondanzaS., GuerraL., De LucaM.1998. Cultivation of human keratinocyte stem cells: Current and future clinical applications. Med. Biol. Eng. Comput., 36:778–790.
32.
RemingtonJ., WangX., HouY., ZhouH., BurnettJ., MuirheadT., UittoJ., KeeneD.R., WoodleyD.T., ChenM.2009. Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol. Ther., 17:26–33.
33.
RobbinsP.B., LinQ., GoodnoughJ.B., TianF.L., ChenX., KhavariP.A.2001. In vivo restoration of laminin 5 β3 expression and function in junctional epidermolysis bullosa. Proc. Natl. Acad. Sci. U.S.A., 98:5193–5198.
ThompsonJ.F., HayesL.S., LloydD.B.1991. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene, 103:171–177.
36.
TolarJ., Ishida-YamamotoA., RiddleM., McElmurryR.T., OsbornM., XiaL., LundT., SlatteryC., DittoJ., ChristianoA.M., WagnerJ.E., BlazarB.R.2009. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood, 113:1167–1174.
37.
UittoJ., PulkkinenL.1996. Molecular complexity of the cutaneous basement membrane zone. Mol. Biol. Rep., 23:35–46.
38.
WongT., GammonL., LiuL., MellerioJ.E., Dopping-HepenstalP.J., PacyJ., EliaG., JefferyR., LeighI.M., NavsariaH., McGrathJ.A.2008. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol., 128:2179–2189.
39.
WoodleyD.T., KruegerG.G., JorgensenC.M., FairleyJ.A., AthaT., HuangY., ClianL., KeeneD.R., ChenM.2003. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J. Invest. Dermatol., 121:1021–1028.
40.
WoodleyD.T., KeeneD.R., AthaT., HuangY., LipmanK., LiW., ChenM.2004a. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat. Med., 10:693–695.
41.
WoodleyD.T., KeeneD.R., AthaT., HuangY., RamR., KasaharaN., ChenM.2004b. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol. Ther., 10:318–326.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
